Dr Reddy's Laboratories announced that it has launched Valganciclovir tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE (Valganciclovir) tablets in the US market, approved by the United States Food & Drug Administration (USFDA).
The VALCYTE (Valganciclovir) tablets brand had US sales of approximately USD 440 million MAT for the most recent twelve months ending in October 2014 according to IMS Health.
Shares of the company declined Rs 124, or 3.68%, to trade at Rs 3,249.75. The total volume of shares traded was 22,392 at the BSE (11.50 a.m., Tuesday).